IDT Biologika buys vax plant from Aeras; Biogen reaches carbon neutrality; Merck tries data mining

> IDT Biologika has formed a partnership with nonprofit TB vaccine vaccine developer Aeras that includes it buying an Aeras manufacturing plant in the U.S. Release

> BioNTech AG has contracted with Siemens to build a paperless manufacturing plant for its cancer vaccine therapies. Release

> German restructuring firm Mutares AG has sold CMO Suir Pharma Ireland to the strategic investor Saneca Pharmaceuticals. Release

> Vin Nguyen of Corona, CA, has pleaded guilty to federal charges that he and others sold back into the legitimate supply chain $6.5 million in prescription meds that they had bought illegally. Release

> Investing in more energy efficient manufacturing facilities has helped biotech Biogen ($BIIB) to attain carbon neutrality. Release

> Merck ($MRK) has turned to data mining company Enigma to help it focus its supply chain and manufacturing operations, particularly in relation to public tender demand. Story

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.